Overexpression of alpha-synuclein following methamphetamine: is it good or bad?
- PMID: 17105917
- DOI: 10.1196/annals.1369.019
Overexpression of alpha-synuclein following methamphetamine: is it good or bad?
Abstract
alpha-Synuclein is a presynaptic protein involved in various degenerative disorders now defined as synucleinopathies. These include neurological diseases that share a few pathological features consisting of aggregates of both normal and altered alpha-synuclein within specific neuronal populations and/or glial cells. The prototype of synucleinopathies is represented by Parkinson's disease (PD) in which alpha-synuclein is identified as a constant component of neuronal pale eosinophilic inclusions: "the Lewy Bodies." In the present article, we discuss the potential significance of amphetamine-induced overexpression of alpha-synuclein in light of clinical findings showing neurodegeneration following overexpression of alpha-synuclein and recent experimental studies that measured increased expression of alpha-synuclein following amphetamine derivatives.
Similar articles
-
Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.Brain Res Bull. 2005 May 15;65(5):405-13. doi: 10.1016/j.brainresbull.2005.02.022. Brain Res Bull. 2005. PMID: 15833595
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
-
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.Neurosci Lett. 2006 Mar 20;396(1):67-72. doi: 10.1016/j.neulet.2005.11.012. Epub 2005 Dec 5. Neurosci Lett. 2006. PMID: 16330147
-
Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein.J Neurosci Res. 2005 Apr 15;80(2):247-59. doi: 10.1002/jnr.20446. J Neurosci Res. 2005. PMID: 15765523
-
Protein aggregation mechanisms in synucleinopathies: commonalities and differences.J Neuropathol Exp Neurol. 2007 Nov;66(11):965-74. doi: 10.1097/nen.0b013e3181587d64. J Neuropathol Exp Neurol. 2007. PMID: 17984679 Review.
Cited by
-
Model fusion, the next phase in developing animal models for Parkinson's disease.Neurotox Res. 2007 Apr;11(3-4):219-40. doi: 10.1007/BF03033569. Neurotox Res. 2007. PMID: 17449461 Review.
-
Snca and Bdnf gene expression in the VTA and raphe nuclei of midbrain in chronically victorious and defeated male mice.PLoS One. 2010 Nov 23;5(11):e14089. doi: 10.1371/journal.pone.0014089. PLoS One. 2010. PMID: 21124898 Free PMC article.
-
Vacuolar Protein Sorting Genes in Parkinson's Disease: A Re-appraisal of Mutations Detection Rate and Neurobiology of Disease.Front Neurosci. 2016 Nov 24;10:532. doi: 10.3389/fnins.2016.00532. eCollection 2016. Front Neurosci. 2016. PMID: 27932943 Free PMC article. Review.
-
Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice.J Addict Prev. 2014;2(2):6. J Addict Prev. 2014. PMID: 25621291 Free PMC article.
-
Atypical Parkinsonism: Methamphetamine may play a role.Clin Case Rep. 2022 May 5;10(5):e05808. doi: 10.1002/ccr3.5808. eCollection 2022 May. Clin Case Rep. 2022. PMID: 35540713 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials